Rusatom Healthcare has identified a general designer and contractor for the construction of a radionuclide therapy center in Lipetsk

2022

Contract for design and survey work on the construction of radionuclide therapy centers in Lipetsk and Ufa

On July 25, 2022, the Rusatom Healthcare division, which accumulates the expertise of Rosatom State Corporation in the field of health, and the consortium (Novaya Uralskaya Kompaniya LLC, Rubin LLC, Construction and Installation Department - 1 Ecologist Bashspetsneftestroy LLC, Medtech Alliance LLC) signed an agreement on the implementation of design and survey work for the construction of buildings of radionuclide therapy centers in the city of Lipetsk and Ufa. This was reported by representatives of Rusatom Healthcare. Read more here.

Positive conclusion of Glavgosexpertiza of Russia on design and estimate documentation

On May 13, 2022, Rosatom announced that the Rusatom Healthcare division received a positive opinion from the Glavgosexpertiza of Russia FAA on design estimates and engineering survey results for the facilities "Creation and Operation of a Radionuclide Therapy Center in the Republic of Bashkortostan" and "Creation and Operation of a Radionuclide Therapy Center in the city of Lipetsk." The construction of nuclear medicine centers will begin in 2022. Read more here.

2021: Agreement with RIP for design and survey work

JSC Rusatom Healthcare and LLC Radioisotope Devices have signed an agreement on the implementation of design and survey work for the construction of a building for a radionuclide therapy center in the city of Lipetsk. The company "Rusatom Healthcare" announced this on August 5, 2021.

The project of the center is being implemented within the framework of an investment agreement between the government of the Lipetsk region and JSC Rusatom Healthcare. Its goal is to increase the availability, timeliness and quality of cancer care for the population of the Lipetsk region and residents of neighboring regions.

According to the previously conducted competitive procedure, the Chelyabinsk company Radioisotope Devices LLC will develop design estimates for the passage of the Glavgosexpertiza of Russia FAA. The first two stages of engineering surveys and development of design documentation should be completed by the end of 2021.

{{quote 'author = said Natalia Komarova, General Director of JSC "Rusatom Healthcare." | The implementation of the project will make it possible to fill the shortage of specialized medical care for patients in the treatment of cancer. Thanks to the high level of functioning of the oncological service and the regional health care system, the center in Lipetsk will become one of the best in the country. The coordinated efforts of the teams "Rusatom Healthcare" and "Radioisotope devices" will make it possible to ensure operation taking into account the schedule agreed by the contract,}}

Шаблон:Quote 'author = noted Anton Krepp, General Director of Radioisotope Devices LLC.

The modern center for radionuclide therapy will be created on the basis of the Lipetsk Regional Oncological Dispensary and will be able to provide more than 2800 services for the diagnosis and treatment of cancer by radionuclide therapy. The center will ensure the accessibility of the population to the services of high-tech medical and palliative care with the use of current radiopharmaceuticals. The first patients are scheduled to be admitted in 2023.

2020: Plans for the construction of an interregional center for radionuclide therapy

On September 11, 2020, it became known that an interregional center for radionuclide therapy will be built in Lipetsk. An agreement was signed between the Government of the Lipetsk Region and Rusatom Healthcare JSC (integrator in the field of radiation technologies in medicine and industry of Rosatom State Corporation) to create the Lipetsk Regional Oncological Dispensary, the first project from the investment program implemented by Rosatom State Corporation to create a network of radionuclide therapy centers in the Russian Federation. The document was signed by the head of the Lipetsk region administration Igor Artamonov and the general director of Rusatom Healthcare JSC Alexander Shibanov.

The meeting of the head of the administration of the Lipetsk region Igor Artamonov (center) with the general director of Rusatom Healthcare JSC Alexander Shibanov (right). Photo source: липецкаяобласть.рф

Lipetsk region has become one of the first Russian regions where Rosatom's radionuclide therapy center will appear. This will open up opportunities for the treatment of cancer. Patients will receive better and more affordable care, noted the head of the region Igor Artamonov

According to Alexander Shibanov, the implementation of the Center for Radionuclide Therapy in the Lipetsk Region will allow the provision of high-tech and palliative medical care services to both the population of the region and the population of the adjacent constituent entities of the Russian Federation of the Central, Southern and Volga Federal Districts.

We had several factors why we determined that we were working with your region. The first is the support and active position of the regional leadership, which quickly and quickly agreed on the issue of allocating a land plot on the basis of an oncological dispensary in the city itself. The second key factor is a strong medical service, a strong oncological service[1], said Alexander Shibanov at a meeting with the head of the region

The project involves the creation in the region of a high-tech center specializing in the use of nuclear medicine technologies for the diagnosis and treatment of diseases of organs and systems of the human body. The key medical technology of the future center will be the use of radiopharmaceuticals based on isotope medical products for direct therapeutic effects on pathological foci.

According to the LipetskMedia.ru portal, the volume of investments in the project will amount to 1.26 billion rubles, up to 800 people a year will be able to undergo treatment at the center.

The first patient is scheduled to be admitted in the first quarter of 2023, and from the beginning of its operation, the center will provide medical services to its patients using radiopharmaceuticals based on 131I, 89Sr, 153Sm, and with the launch in 2025 of its own GMP plant for the production of FPM based on 223Ra, 225Ac and 177Lu, the center will significantly expand its capabilities to provide patients with high-tech and palliative medical care.

The structure of the pilot center is represented by consultation rooms for primary and repeated consultations of specialist doctors, a day hospital for the possibility of performing medical interventions in the process of a patient's short stay in a medical institution, as well as 2 profiled tent departments with a round-the-clock stay to provide patients with radionuclide therapy services^[2].

Notes